Search

Your search keyword '"D'Aoust, Marc‐André"' showing total 156 results

Search Constraints

Start Over You searched for: Author "D'Aoust, Marc‐André" Remove constraint Author: "D'Aoust, Marc‐André"
156 results on '"D'Aoust, Marc‐André"'

Search Results

4. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities

6. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates

9. Heterologous expression of influenza haemagglutinin leads to early and transient activation of the unfolded protein response in Nicotiana benthamiana.

10. Molecular responses of agroinfiltrated Nicotiana benthamiana leaves expressing suppressor of silencing P19 and influenza virus‐like particles.

11. A genome‐edited N. benthamiana line for industrial‐scale production of recombinant glycoproteins with targeted N‐glycosylation

12. In planta expression of active bacterial GDP‐6‐deoxy‐d‐lyxo‐4‐hexulose reductase for glycan modulation

13. An oligosaccharyltransferase from Leishmania donovani increases the N-glycan occupancy on plant-produced IgG1

14. Heterologous expression of influenza hemagglutinin leads to early and transient activation of the unfolded protein response inNicotiana benthamiana

21. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

26. Durability and Cross-Reactivity of Immune Responses Induced by an AS03-Adjuvanted Plant-Based Recombinant Virus-Like Particle Vaccine for COVID-19

28. Plant N-glycan profiling of minute amounts of material

29. Phase 2 Randomized Trial of an AS03 Adjuvanted Plant-Based Virus-Like Particle Vaccine for Covid-19 in Healthy Adults, Older Adults and Adults with Comorbidities

30. Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates

32. Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants

35. Production of Biopharmaceuticals in Nicotiana benthamiana—Axillary Stem Growth as a Key Determinant of Total Protein Yield

39. Cell wall biochemical alterations during Agrobacterium‐mediated expression of haemagglutinin‐based influenza virus‐like vaccine particles in tobacco

40. pH Gradient Mitigation in the Leaf Cell Secretory Pathway Attenuates the Defense Response of Nicotiana benthamianato Agroinfiltration

41. Case study: Application of mass spectrometry for evaluation of N-glycans, lipids and protein impurities in a plant-made influenza VLP vaccine

42. Generation and characterization of a trackable plant-made influenza H5 virus-like particle (VLP) containing enhanced green fluorescent protein (eGFP)

45. Multiplexed, targeted gene editing in Nicotiana benthamiana for glyco‐engineering and monoclonal antibody production

48. Multiplexed, targeted gene editing in Nicotiana benthamiana for glyco-engineering and monoclonal antibody production.

Catalog

Books, media, physical & digital resources